Aiolos Bio launches with ex-Gyroscope CEO at the helm, nearly $250M to advance severe asthma med

A consistent theme of 2023 has been that advanced assets attract seismic capital and a newly launched biotech adds more proof to the pile.

Aiolos Bio is jetting out of stealth with a $245 million series A, igniting its startup thrusters en route to a phase 2 trial for its lead asset to treat severe asthma. That asset, AIO-001, is an anti-TSLP antibody licensed from Jiangsu Hengrui Pharmaceuticals, a Chinese biotech that’s retained rights to the greater China market.